Monumental Financial Group Inc. Sells 108 Shares of Eli Lilly and Company (NYSE:LLY)

Monumental Financial Group Inc. lowered its stake in shares of Eli Lilly and Company (NYSE:LLY) by 3.7% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 2,803 shares of the company’s stock after selling 108 shares during the period. Eli Lilly and Company comprises approximately 1.0% of Monumental Financial Group Inc.’s investment portfolio, making the stock its 16th biggest holding. Monumental Financial Group Inc.’s holdings in Eli Lilly and Company were worth $1,634,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in LLY. Simon Quick Advisors LLC lifted its holdings in Eli Lilly and Company by 10.5% during the fourth quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company’s stock valued at $1,706,000 after purchasing an additional 278 shares during the last quarter. Clear Harbor Asset Management LLC purchased a new stake in Eli Lilly and Company during the fourth quarter valued at about $363,000. Hartline Investment Corp lifted its holdings in Eli Lilly and Company by 1.1% during the fourth quarter. Hartline Investment Corp now owns 21,934 shares of the company’s stock valued at $12,786,000 after purchasing an additional 248 shares during the last quarter. Meritage Portfolio Management lifted its holdings in Eli Lilly and Company by 23.4% during the fourth quarter. Meritage Portfolio Management now owns 6,377 shares of the company’s stock valued at $3,717,000 after purchasing an additional 1,208 shares during the last quarter. Finally, WASHINGTON TRUST Co lifted its holdings in Eli Lilly and Company by 16.5% during the fourth quarter. WASHINGTON TRUST Co now owns 18,892 shares of the company’s stock valued at $11,013,000 after purchasing an additional 2,671 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

NYSE LLY traded up $8.64 on Friday, reaching $733.51. 2,009,249 shares of the company’s stock traded hands, compared to its average volume of 2,265,427. Eli Lilly and Company has a 12 month low of $380.77 and a 12 month high of $800.78. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. The stock has a 50-day simple moving average of $761.79 and a 200 day simple moving average of $667.10. The stock has a market cap of $696.95 billion, a PE ratio of 126.47, a P/E/G ratio of 1.60 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The firm had revenue of $9.35 billion for the quarter, compared to analysts’ expectations of $8.95 billion. During the same quarter last year, the business earned $2.09 earnings per share. The business’s revenue was up 28.1% on a year-over-year basis. As a group, research analysts predict that Eli Lilly and Company will post 12.51 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on LLY. Wells Fargo & Company increased their price target on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a report on Tuesday, February 6th. JPMorgan Chase & Co. increased their price target on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the stock an “overweight” rating in a report on Friday, March 15th. BMO Capital Markets increased their price target on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a report on Wednesday, February 7th. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Finally, TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $728.05.

Insider Transactions at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 54,032 shares of the firm’s stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $645.07, for a total value of $34,854,422.24. Following the transaction, the insider now owns 99,488,598 shares in the company, valued at $64,177,109,911.86. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.